Benzinga | May 21, 2021 06:33AM EDT

UBS Initiates Coverage On AnaptysBio with Neutral Rating, Announces Price Target of $29

UBS analyst Eliana Merle initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Neutral rating and announces Price Target of $29.